April 27, 2022
Source: Press Release, Basel
- SOTIO will share interim safety and efficacy results from SOTIO’s AURELIO-03 study on Saturday, June 4
- AURELIO-03 is a Phase 1/1b dose escalation study of the interleukin-15 superagonist SOT101 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors
SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, announced today that it will deliver an oral presentation featuring interim safety and efficacy data from the Phase 1/1b AURELIO-03 study with its IL-15 superagonist, SOT101, as monotherapy and in combination with pembrolizumab at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting 2022, taking place in Chicago, Illinois from June 3-7, 2022.
Interim data from AURELIO-03 will be presented by Dr. Elena Garralda from the Vall D’Hebron Institute of Oncology, Barcelona, Spain.
Oral Presentation Details:
Title: Interim safety and efficacy results from AURELIO-03: A phase 1 dose escalation study of the IL-2/IL-15 receptor βγ superagonist SOT101 as a single agent and in combination with pembrolizumab in patients with advanced solid tumors.
Presenting Author: Elena Garralda, MD
Abstract Number: 2502
Location: Hall B1
Session Type: Oral Abstract Session
Session Title: Developmental Therapeutics—Immunotherapy
Session Date: Saturday, June 4, 2022
Session Time: 1:15 PM-4:15 PM CDT
Selected presentation materials will be made available on the SOTIO Biotech website once the presentation concludes.
SOT101 is an interleukin 15 (IL-15) superagonist currently being evaluated in a global multicenter open-label Phase 1/1b study to evaluate the safety and preliminary efficacy as a monotherapy and in combination with pembrolizumab in patients with advanced solid tumors.